Early treatment of ocular hypertension appears to reduce the risk of developing glaucoma, especially in individuals at the highest risk, according to a report in the March issue of Archives of Ophthalmology, one of the JAMA/Archives journals. However, this strategy may not offer an absolute benefit in individuals at low risk.
Glaucoma is one of the most common causes of blindness in the United States and worldwide, according to background information in the article. High pressure within the eye--referred to as elevated intraocular pressure or ocular hypertension--is a leading risk factor for the development of primary open-angle glaucoma, the most common type. It is also the only risk factor that is modifiable.
"It is estimated that 4 percent to 7 percent of the U.S. population older than 40 years has ocular hypertension," the authors write. "There is substantial controversy on how to manage this large group of individuals who are at higher risk of developing glaucoma than the general population." The Ocular Hypertension Treatment Study previously demonstrated that lowering intraocular pressure in this population could delay or prevent the onset of glaucoma, but the optimal timing for initiating treatment has yet to be determined.
Michael A. Kass, M.D., of Washington University School of Medicine, St. Louis, and colleagues in the Ocular Hypertension Treatment Study Group compared the safety and efficacy of earlier vs. later treatment in preventing glaucoma among 1,636 individuals with elevated intraocular pressure. Participants were randomly assigned to either observation or topical ocular pressure-lowering medication. Those assigned to receive medication were treated for a median (midpoint) time of 13 years, whereas the observation group was monitored for a median time of 7.5 years and then received medication for a median of 5.5 years.
Overall, 22 percent of participants in the original observation group and 16 percent in the original medication group developed glaucoma after 13 years--meaning early treatment was associated with a 27 percent reduction in the risk of glaucoma. Among the one-third of individuals who had the highest initial risk of developing glaucoma--as determined by factors such as age, corneal thickness and baseline intraocular pressure--40 percent in the observation group and 28 percent in the medication group developed glaucoma. There was little evidence of adverse events associated with the medication.
"The data presented suggest that ocular hypertension patients at high risk may benefit from more frequent examinations and from early treatment, taking into consideration age, health status, life expectancy and the patient preference," the authors write. "Conversely, most ocular hypertension patients at low risk could be followed up at less frequent intervals without treatment. Delaying treatment for 7.5 years in low-risk participants resulted in only a small absolute increase in the overall frequency of primary open-angle glaucoma."
The results indicate that an individualized assessment of the risk of developing glaucoma can aid patients and clinicians in making treatment decisions. "Clinicians need to consider the patient's age, health status, life expectancy and personal preferences when making such decisions. Ultimately, the full extent of the penalty for delaying treatment will require longer follow-up to ascertain the incidence and degree of visual impairment by randomization group," the authors conclude.
(Arch Ophthalmol. 2010;128:276-287. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: This study was supported by grants from the National Eye Institute and the National Center on Minority Health and Health Disparities, National Institutes of Health; Merck Research Laboratories; Pfizer Inc; and an unrestricted grant from Research to Prevent Blindness. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Treatment Decisions Remain in the Hands of Clinicians and Patients
The study design attempts to answer the perennial question of whether patients with ocular hypertension should receive pressure-lowering medications, writes Alfred Sommer, M.D., M.H.S., of Bloomberg School of Public Health, Johns Hopkins University, Baltimore, in an accompanying editorial.
"The new Ocular Hypertension Treatment Study data throw interesting light on the issue, though the answer probably remains unchanged: 'It all depends,'" Dr. Sommer writes. "The thoughtful clinical decision depends on whether treating the patient might do more harm than good."
"In the end, the physician is stuck with the persistent problem of whom to treat and whom to watch," they write. "The fascinating article by Kass et al provides interesting insights as to many of the issues at stake, but offers little definitive information to guide us. It probably still makes sense that young patients with lots of high risk factors should receive prophylaxis [preventive therapy], while elderly patients with few risk factors should not. The endless symposia and debates on how best to manage patients with ocular hypertension will probably continue unabated."
(Arch Ophthalmol. 2010;128:363-364. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: Please see the article for additional information, including author contributions and affiliations, financial disclosures, funding and support, etc.
For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail email@example.com. To contact editorial author Alfred Sommer, M.D., M.H.S., call Tim Parsons at 410-955-7619 or e-mail firstname.lastname@example.org.